פּרעזאַדאַנסי קאָנפֿערענץ בילדינג קאָנסענסוס פֿאַר פּראָגרעס אויף ינאַווייטיוו פערזענליכען מעדיצין אין אַ COVID 19 און נאָך COVID 19 וועלט

The third Presidency Conference, organized by the European Alliance for Personalised Medicine (EAPM) saw multi-stakeholder consensus reached on many facets of facilitating innovation in modern-day European healthcare systems, שרייבט עאַפּם אויספֿיר דירעקטאָר דעניס האָרגאַן.

The event held during the auspices of the Germany EU Presidency and is entitled 'Ensuring Access to Innovation and data-rich biomarker space to speed better quality of care for Citizens’, and took place in a virtual environment on 12 October.

 The meeting of multidisciplinary personalised medicine experts followed three successful annual congresses in Belfast, Brussels and Milan, plus seven annual Presidency Conferences.

What happened this morning?

As ever, the Presidency conference ווייַזן פאַרשידענע אַבדזשעקטיווז וואָס ביידע די ציבור און פּריוואַט סעקטאָר קענען שטיצן, מיט די מיינונג צו לאָזן די אי.יו. פאָרשטעלן אַ פּראָסט אָביעקטיוו. עס גענומען שטעלן אין אַ פאָוקיסט פֿאָרמאַט צו לאָזן באַטאָנען ישוז צו זיין טאַקאַלד און צו האָבן אַ דיאַלאָג מיט פּאַלאַסימייקערז.

EU4Health programme leader Cristian Busoi MEP spoke in the morning and, for the afternoon session, further MEPs are headlined to speak, as well as EMA and Commission representatives. There were more than 200 attendees at the conference this Monday morning, marking the conference as a singular success. And the EU4Heath programme, which is destined to take a big step forward, was also discussed at the conference. The draft compromise amendments will be voted on in the ENVI committee, which means that, for the first time, the European Parliament will be having its say on the proposal. 

פֿאַר די afternoon session which starts at 14h, sessions include  a) Biomarker testing in the field of Alzheimer's and related dementia; b) Session IV: Propelling Health Care with Advanced Therapy Medicinal Products (ATMPs) and c) Closing Session: Realising the Potential of Data & Early Diagnosis through Biomarker Testing & Molecular Diagnostics.

אַדווערטייזמאַנט

די טאג פיטשערד אַ full and productive session on the current hot topic of the Pharmaceutical Strategy, rational allocation of resources in a COVID and post COVID world, European Data Space, Gene therapy plus value-based outcomes and biomarkers/molecular diagnostics.

Biomarkers were discussed recently at an EAPM satellite event which took place at the ESMO Congress and a pre-געשעעניש קייַלעכיק טיש on the topic of biomarkers and molecular diagnosis took place ahead of the main Conference in Brussels which led to the academic publication entitled ‘Bringing Greater Accuracy to Europe’s Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology’. 

Key statements

קריסטלעך בוסאָי מעפּ געזאגט: "Action is necessary at a co-operative and EU level - in gaining new insights into diseases, personalised medicine is already becoming the dominant therapy for cancer and a host of other afflictions.

"Quality assurance needs to be further developed to respond to patients requirements. And affordability is the most crucial issue - can we 'afford' to beat cancer?" 

AstraZeneca Europe and Canada Executive Vice President Iskra Reic said: “It is vital to learn from the crisis and share and come together and learn. It needs multiple partners working together across health-care ecosystems.”

On the topic of cancer, meanwhile, Christine Chomienne, vice chairwoman, Mission Board for Cancer, and professor of cellular biology at the Université Paris Diderot said: “We need to change the frame of mind on cancer culture – for prevention, for policymakers, for reimbursement, but always with very strong evidence.”

בעשאַס די קאָנפֿערענץ, EUnetHTA Chief Operating Officer Marcus Guardian said: “We have proven efficiency gains from EU-level co-ordination – but this requires a robust mechanism with clear rules, balanced by flexibility in national implementation.” 

He added: “We also need to recall that reimbursement and pricing are not covered by the proposal and that will remain a competence of member states. EU cooperation is needed to ensure constant exchange of information between HTA authorities in the EU.”

צווישן די גערעדט אויף דער געשעעניש געווען Mary Baker, former president of the European Brain Council. She said: “There is a need for the cooperation of society. We need the science to get the answers but they are no use if they just stay in the laboratories. We need to show we can work together.” 

In more sobering news, the health programme has seen its budget slashed by the Council  to €1.7 billion from the €9.4bn proposed by the Commission in May — which has provoked criticism in the Brussels health bubble, described as “short-sighted penny-pinching in the face of a once in a lifetime health crisis”. And, in September, Commission President Ursula von der Leyen called on MEPs to fight for more health money.

 The report on the conference will be issued later this week.

שער דעם אַרטיקל: